Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wholesalers Drawing DoJ Scrutiny In Drug Diversion Investigations

Executive Summary

Wholesalers will face increasing Justice Department scrutiny in pharmaceutical diversion cases, a federal prosecutor predicted

You may also be interested in...



Spitzer squeezing secondary market

Cardinal Health is the first wholesaler to settle with the New York Attorney General's office regarding trading in the secondary wholesale market. According to the AG's office, Cardinal bought and sold drugs in the secondary market without appropriate regard for drug integrity and risk of diversion. Under the settlement, Cardinal agrees to pay $10 million and adopt a set of Wholesaler Safe Product Practices. The investigation into improper trading practices of other wholesalers will continue, the AG says. AmerisourceBergen and McKesson have also been subpoenaed as part of the investigation (1"The Pink Sheet" April 18, 2005, p. 23). Wholesaler distribution practices that allow drug diversion may emerge as a focus of prosecution at the federal level as well (2"The Pink Sheet" Dec. 12, 2005, p. 25)...

Spitzer squeezing secondary market

Cardinal Health is the first wholesaler to settle with the New York Attorney General's office regarding trading in the secondary wholesale market. According to the AG's office, Cardinal bought and sold drugs in the secondary market without appropriate regard for drug integrity and risk of diversion. Under the settlement, Cardinal agrees to pay $10 million and adopt a set of Wholesaler Safe Product Practices. The investigation into improper trading practices of other wholesalers will continue, the AG says. AmerisourceBergen and McKesson have also been subpoenaed as part of the investigation (1"The Pink Sheet" April 18, 2005, p. 23). Wholesaler distribution practices that allow drug diversion may emerge as a focus of prosecution at the federal level as well (2"The Pink Sheet" Dec. 12, 2005, p. 25)...

Daytrana Post-Marketing Study Of Skin Sensitization Urged By Committee

Post-marketing surveillance and study of skin sensitization with Shire/Noven's Daytrana methylphenidate patch for attention deficit/hyperactivity disorder were recommended by FDA's Psychopharmacologic Drugs Advisory Committee at its Dec. 2 meeting

Related Content

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel